{"filings":[{"id":483317,"accession_number":"0001193125-26-228016","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-05-18T13:06:24+00:00","items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Soleno acquisition by Neurocrine Biosciences completed; all shares bought for $53.00 each","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired May 15 with 88.9% of shares tendered; merger closed May 18, 2026.","Stockholders received $53.00 per share in cash; total offer consideration funded via Neurocrine cash.","All pre-merger directors and officers resigned; new directors and officers from Neurocrine appointed.","Shares to be delisted from Nasdaq and deregistered with SEC; Form 15 to be filed.","Loan agreement with Oxford Finance and 2014 ESPP terminated effective upon merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93113,"accession_number":"0001193125-26-144511","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Soleno withdraws EU marketing application for VIOKAT (PWS hyperphagia)","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Voluntarily withdrew MAA for VIOKAT (diazoxide choline) from EMA for Prader-Willi syndrome hyperphagia.","Decision based on business and strategic considerations; company may re-engage with regulators later.","VIOKAT is marketed in the US as VYKAT XR for adults and children aged 4+ with PWS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93112,"accession_number":"0001193125-26-142911","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neurocrine to acquire Soleno for $53.00/share in $2.9B all-cash transaction","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal price $53.00 per share; total equity value ~$2.9B; Soleno board recommends shareholders tender.","VYKAT XR generated $190M revenue in 2025, including $92M in Q4 2025; IP expected to extend to mid-2040s.","Conditions include tender of >50% of shares, HSR clearance, no material adverse effect, and customary representations.","Termination fee: $95.25M from Soleno under certain circumstances; $141.5M from Neurocrine if antitrust blocks deal.","Principal stockholders holding ~1.01% of shares have agreed to tender and vote in favor via support agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104471,"accession_number":"0001193125-26-107429","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Soleno amends bylaws with advance notice changes, forum selection, governance updates","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective March 16, 2026.","Updated advance notice provisions for stockholder proposals and director nominations.","Amendments reflect recent Delaware law changes and include a forum selection clause.","Certain governance updates and technical/clarifying changes were also made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104470,"accession_number":"0001193125-26-073209","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics appoints Jennifer Fulk as CFO, succeeding retiring James Mackaness","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Fulk appointed CFO effective March 2, 2026; base salary $525k, target bonus 45%, option for 67,660 shares, RSUs for 39,200 shares.","James Mackaness retiring by end of March 2026, will consult through December 2026 for smooth transition.","Fulk brings 20+ years experience including 15 years at Eli Lilly, most recently CFO/COO at 120Water and CFO at Talkspace.","Fulk will participate in Soleno's Key Executive Change in Control and Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104469,"accession_number":"0001193125-26-071528","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.","Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).","859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.","Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.","First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":190405000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104468,"accession_number":"0001193125-26-021229","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Soleno Therapeutics approves FY2026 salary hikes, FY2025 bonuses, equity grants, and new severance plan for NEOs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO base salary raised to $765k; CFO to $529k; CCO to $515k; SVP Regulatory to $447k.","FY2025 cash bonuses: CEO $487,740; CFO $218,708; CCO $201,588; SVP Reg $161,784.","CEO granted 131,400 stock options and 114,200 RSUs; other NEOs received smaller awards.","New Key Executive Change in Control/Severance Plan offers up to 24 months salary + 150% target bonus + full equity acceleration in change-in-control event.","Outside a change-in-control, CEO gets 18 months salary, 100% target bonus, and 25% equity acceleration; other execs get 9-12 months with no equity acceleration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104467,"accession_number":"0001193125-26-009886","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.","1,250 patient start forms since launch (207 in Q4), ~12.5% of U.S. PWS addressable market.","630 unique prescribers, 136 new in Q4; discontinuation rate ~12% for adverse events.","Achieved profitability and positive cash flow; year-end cash ~$500M after $100M buyback.","Company responded to EMA Day 120 questions; ~60% of total lives covered."],"consensus_eps_estimate":null,"consensus_eps_actual":0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":190405000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120762,"accession_number":"0001193125-25-275674","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Soleno initiates $100M accelerated share repurchase; amends loan facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $100M accelerated share repurchase with Jefferies; initial delivery of ~1,511,553 shares.","Repurchase expected to complete in Q1 2026; final shares based on VWAP less discount.","Amended Oxford loan facility to permit ASR; $50M committed Term C/D loans removed; remaining $100M uncommitted.","CEO cites Q3 2025 profitability and confidence in VYKAT XR launch as rationale for buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120761,"accession_number":"0001193125-25-264658","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports Q3 net income $26M, first profitable quarter; VYKAT XR revenue $66M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue of $66.0M from VYKAT XR launch (first revenue, vs $0 prior year); net income $26.0M ($0.47 diluted EPS) vs net loss of $76.6M in Q3 2024.","1,043 patient start forms and 764 active patients on VYKAT XR as of Sept 30, 2025; 494 unique prescribers and over 132M lives covered since March approval.","Cash and securities at $556.1M, including $230M gross proceeds from July common stock offering; operating cash flow of $43.5M in Q3.","Sequential product revenue more than doubled from $32.7M in Q2 2025; R&D expense fell to $8.4M from $30.1M, and SG&A to $33.8M from $49.2M.","Appointed Mark W. Hahn to Board of Directors and Audit Committee; contingent consideration liability for Essentialis earnout estimated at $19.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":98675000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120760,"accession_number":"0001193125-25-237854","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics appoints Mark W. Hahn to Board and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to 7 seats; Hahn appointed as Class II director, term expiring at 2028 annual meeting.","Hahn received 10,046 RSUs vesting over 3 years under Outside Director Compensation Policy.","Hahn most recently was CFO of Verona Pharma through its acquisition by Merck for ~$10B in Oct 2025.","Previously CFO of Dova Pharma (acquired by Sobi for up to $915M) and Cempra (IPO lead).","Hahn brings nearly 30 years of CFO-level experience; certified CPA in Maryland and North Carolina."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137352,"accession_number":"0001193125-25-199882","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Soleno reports death of VYKAT XR patient; company says not drug-related","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.","Treating physician and Soleno assessed the death as not related to VYKAT XR treatment.","Soleno reaffirms VYKAT XR safety profile and urges use per FDA-approved label.","Company will not comment on future adverse events unless directly linked to VYKAT XR and unexpected per label.","Prader Willi Syndrome patients have reduced life expectancy; mean age of death is 29.5 years per 40-year study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137351,"accession_number":"0001193125-25-182184","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Soleno management to present at Guggenheim/Piper Sandler non-deal roadshow Aug 18-19","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Senior management will participate in pre-scheduled investor meetings August 18-19, 2025.","Roadshow is non-deal; hosted by Guggenheim Securities and Piper Sandler.","Corporate presentation attached as Exhibit 99.1, but no specific new data extracted from exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137350,"accession_number":"0001193125-25-174458","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Q2 2025: $32.7M product revenue from VYKAT XR launch; net loss $4.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue, net $32.7M for Q2 2025, first quarter with VYKAT XR sales (launched April 14).","Net loss $(4.7)M or ($0.09) per share vs. $(21.9)M ($0.57) in Q2 2024.","Cash, equivalents and marketable securities $293.8M at June 30; subsequent $230M equity offering in July.","Launch metrics: 646 patient start forms, 295 unique prescribers, >100M lives covered by end of Q2.","MAA for DCCR submitted to EMA; contingent consideration liability for sales milestones estimated at $18.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32657000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137349,"accession_number":"0001193125-25-157728","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.","Underwriters have 30-day option to purchase up to an additional 352,941 shares at same price.","Proceeds to fund commercialization of VYKAT XR (diazoxide choline) for Prader-Willi syndrome, approved March 26, 2025.","Also funds EU regulatory/market development, R&D, and general corporate purposes.","Offering expected to close July 11, 2025; joint book-runners: Goldman Sachs, Guggenheim, TD Cowen, Cantor, Oppenheimer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137348,"accession_number":"0001193125-25-157303","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno expects Q2 2025 VYKAT XR net revenue of $31-33M; cash at $293.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary net revenue of VYKAT XR for Q2 2025: $31.0-$33.0 million.","Cash, equivalents & marketable securities at June 30, 2025: ~$293.8 million.","Received 646 patient start forms from ~295 unique prescribers since March 26, 2025 approval.","Debt outstanding under Oxford Financing LLC loan: ~$50.0 million, unchanged.","First revenue quarter for VYKAT XR; financial close and review ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":32657000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154666,"accession_number":"0001193125-25-137047","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Soleno Therapeutics stockholders elect two Class II directors and ratify auditor at 2025 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Anish Bhatnagar re-elected with 42,591,113 votes for (92.3% of voted); William Harris re-elected with 32,331,183 votes for (70.0%).","Appointment of CBIZ CPAs P.C. as independent auditor ratified with 47,253,371 votes for, 8,580 against, 12,015 abstentions.","47,273,966 shares represented (94.7% of outstanding); quorum established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154665,"accession_number":"0001193125-25-114891","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.","Q1 net loss $43.8M ($0.95 EPS) vs $21.4M ($0.59) a year ago; no revenue yet.","Cash and marketable securities $290.0M; operating cash use $32.8M in quarter.","R&D expense $13.5M; SG&A $29.3M, reflecting launch preparation costs.","MAA submission to EMA for DCCR on track for Q2 2025; contingent consideration liability $17.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154664,"accession_number":"0001193125-25-085810","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Soleno Therapeutics replaces auditor Marcum with CBIZ CPAs; no accounting disagreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on April 17, 2025; CBIZ CPAs engaged April 18, 2025 for FY 2025.","Marcum's 2024 and 2023 audit reports had no adverse opinions except an adverse opinion on internal controls due to a material weakness.","No disagreements or reportable events occurred between the Company and Marcum during the relevant periods.","Engagement of CBIZ CPAs was approved by the Audit Committee; prior to engagement, no consultations occurred on accounting matters.","Marcum provided a letter to the SEC agreeing with the statements in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173187,"accession_number":"0001193125-25-064140","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FDA approves Soleno's VYKAT XR for hyperphagia in Prader-Willi syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in PWS; for ages 4+.","Approval based on Phase 3 randomized withdrawal study with mean of 3.3 years prior treatment.","Most common adverse reactions (≥10% and ≥2% over placebo): hypertrichosis, edema, hyperglycemia, rash.","Soleno expects VYKAT XR to be available in the U.S. starting April 2025.","Company launched Soleno One patient support program; conference call/webcast at 5:30 p.m. ET today."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173186,"accession_number":"0001193125-25-039299","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.","Cash, cash equivalents and marketable securities $318.6M at Dec 31, 2024; used $69.1M in operations.","NDA for DCCR (PWS) under FDA Priority Review with PDUFA target March 27, 2025.","Entered loan agreement with Oxford for up to $200M ($50M upfront); completed $158.7M public offering in May 2024.","Appointed Dawn Carter Bir to Board; Matthew Pauls as Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173185,"accession_number":"0001193125-25-012294","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Soleno Therapeutics raises executive base salaries, grants FY2024 bonuses and equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Bhatnagar base salary increased to $739,000 effective Jan 1, 2025; FY2024 cash bonus of $403,200.","CFO Mackaness base salary set at $511,000; FY2024 bonus of $193,200; 31,000 options and 14,500 RSUs awarded.","SVP Hirano base salary $432,000; FY2024 bonus $137,812; 13,800 options and 6,400 RSUs awarded.","Options vest over 4 years (monthly after 1-year cliff); RSUs vest 25% per year over 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190217,"accession_number":"0001193125-24-280509","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics secures up to $200M debt financing from Oxford Finance; initial $50M drawn","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $50 million draw at closing; up to $100 million in milestone tranches tied to FDA approval of DCCR for PWS.","Pro-forma cash, equivalents and marketable securities of $334.7 million as of September 30, 2024 including the draw.","Loan terms: 48-month interest-only period, 60-month maturity (extendable 12 months), floating rate of 1-month SOFR + 5.50%.","Proceeds to support commercial launch activities for DCCR (diazoxide choline) extended-release tablets for Prader-Willi syndrome.","Covenants include minimum cash (starting June 30, 2025) and revenue triggers; loan secured by substantially all assets including IP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190216,"accession_number":"0001193125-24-265687","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA extends PDUFA date for Soleno's DCCR NDA to March 27, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA extended review period by three months from Dec 27, 2024, to March 27, 2025.","Extension due to FDA deeming responses to recent info requests a major amendment.","FDA did not cite any safety, efficacy, or manufacturing concerns in correspondence.","NDA for DCCR to treat hyperphagia in Prader-Willi syndrome patients aged 4+.","DCCR has Breakthrough, Fast Track, and Orphan Drug designations in US and EU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190215,"accession_number":"0001193125-24-252054","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Therapeutics Q3 net loss $76.6M; NDA for DCCR in PWS accepted with Priority Review, PDUFA Dec 27, 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA for DCCR (diazoxide choline) for Prader-Willi syndrome accepted by FDA with Priority Review; PDUFA target action date December 27, 2024.","Net loss $76.6M ($1.83/sh) vs $10.9M ($0.95/sh) in Q3 2023; increase driven by non-cash stock-based compensation tied to NDA milestones.","R&D expense $30.1M (includes $18.5M stock comp); G&A expense $49.2M (includes $38.1M stock comp), both up significantly from prior year.","Cash, cash equivalents and marketable securities $284.7M as of Sept 30, 2024; cash used in operations $14.9M in Q3.","Board appointed Dawn Carter Bir and Matthew Pauls assumed Lead Independent Director role."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206717,"accession_number":"0001193125-24-201313","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics board changes: Chairman Mario resigns for health; Dawn Bir appointed as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chairman Ernest Mario resigns effective August 15, 2024 for health reasons; no disagreement with company.","Dawn Carter Bir appointed to board effective August 15, 2024; receives 13,000 RSUs vesting over 3 years.","Matthew Pauls named Lead Independent Director; Andrew Sinclair chairs Compensation Committee.","Bir brings over 30 years biotech experience, led commercial launches at Reata and Pharmacyclics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206716,"accession_number":"0001193125-24-196040","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno reports Q2 2024 net loss of $21.9M; NDA for DCCR in PWS submitted to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome with hyperphagia submitted to FDA.","Cash, cash equivalents and marketable securities of $294.6M as of June 30, 2024.","Net loss of $21.9M ($0.57 per share) for Q2 2024 vs. $8.5M ($0.81 per share) in Q2 2023.","R&D expense $12.3M (Q2 2024) up from $5.1M (Q2 2023) due to NDA submission and launch prep.","Closed $158.7M public offering of 3.45M shares at $46.00 each; BT designation for DCCR granted."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206715,"accession_number":"0001193125-24-181717","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Soleno Therapeutics enters $150M at-the-market equity offering with Jefferies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Soleno may sell up to $150M of common stock from time to time under Sale Agreement with Jefferies.","Jefferies will use commercially reasonable efforts to sell shares as an at-the-market offering.","Commission of 3.0% of gross proceeds; Soleno also reimburses certain expenses.","Offering made under existing S-3ASR registration statement filed on Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206714,"accession_number":"0001193125-24-181329","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Soleno grants performance-based RSUs to executives tied to DCCR NDA milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Anish Bhatnagar receives 850,000 performance-based RSUs; CFO James Mackaness 100,000; SVP Patricia Hirano 85,000.","Vesting: 25% on Aug 1, 2024; 25% on FDA acceptance of DCCR NDA for Prader-Willi syndrome; 50% on FDA approval.","Board increased 2014 Equity Incentive Plan by 2,000,000 shares, approved by 68.6% of votes at June 2024 annual meeting.","Grants aim to bring key employee equity ownership in line with peer group median."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223929,"accession_number":"0001193125-24-172238","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soleno submits NDA to FDA for DCCR to treat Prader-Willi Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA submitted for DCCR (diazoxide choline) extended-release tablets for PWS in patients aged 4+ with hyperphagia.","DCCR holds Breakthrough Therapy and Fast Track designations in the U.S.; Orphan Drug designation in U.S. and EU.","FDA has 60 days to determine if NDA will be accepted; Soleno requested Priority Review (6-month target review).","CEO Anish Bhatnagar called the submission a significant milestone for Soleno and the PWS community."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223928,"accession_number":"0001193125-24-164463","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Soleno Therapeutics enters new office lease for 18,026 sq ft in Redwood City","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5-year lease at 100 Marine Parkway; base rent starts at $57,400/month.","Annual rent escalations of approximately 3% over the lease term.","Company to reimburse landlord for certain operating expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223927,"accession_number":"0001193125-24-156113","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Soleno shareholders elect director, ratify auditor, and approve expanded equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Andrew Sinclair elected as Class I director with 93.3% of votes cast (26.4M for, 1.9M withheld).","Marcum LLP ratified as independent auditor for FY 2024 (29.2M for, 135K against).","Amended 2014 Equity Incentive Plan approved (19.4M for, 8.9M against); share pool set at 5,825,762 shares plus annual 4% evergreen increase.","Voter turnout of 87.7% (29,312,453 of 33,411,329 shares outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223926,"accession_number":"0001193125-24-135478","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Q1 net loss $21.4M; FDA breakthrough therapy for DCCR; NDA mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.4M ($0.59 per share) vs $8.4M loss in Q1 2023; R&D expense rose to $14.6M from $5.3M.","Pro forma cash reserves $307.2M after May 2024 public offering netting $148.8M.","FDA granted Breakthrough Therapy Designation for DCCR in Prader-Willi syndrome; NDA submission on track for mid-2024.","Strengthened leadership: appointed Chief Commercial Officer, VP Europe, VP Human Resources.","Contingent consideration liability for DCCR commercial milestones valued at $12.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223925,"accession_number":"0001193125-24-133322","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Soleno Therapeutics prices $138M public offering of 3M shares at $46/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 3,000,000 shares at $46.00 per share for gross proceeds of ~$138M.","Net proceeds estimated at ~$129.3M after underwriting discounts and expenses.","Underwriters granted 30-day option to purchase up to 450,000 additional shares.","Proceeds to fund R&D for DCCR (Prader-Willi Syndrome) and general corporate purposes.","Offering expected to close on or about May 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223924,"accession_number":"0001193125-24-122237","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soleno gets FDA Breakthrough Therapy Designation for DCCR in Prader-Willi Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants Breakthrough Therapy Designation for DCCR (diazoxide choline) in adults/children ≥4 yrs with PWS and hyperphagia.","First ever Breakthrough Therapy Designation for a drug developed for PWS; based on Phase 3 program data.","NDA submission for DCCR in PWS remains on track for mid-2024.","DCCR also has Orphan Drug Designation in US and EU and Fast Track Designation in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223923,"accession_number":"0001193125-24-104871","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Gwen Melincoff not to stand for re-election at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melincoff notified Board on April 17, 2024 that she will not seek re-election at the 2024 AGM.","Decision not due to any disagreement with Soleno Therapeutics or its Board.","Melincoff will continue as director until the 2024 Annual Meeting of Stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243306,"accession_number":"0001193125-24-061288","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"Soleno reports Q4 net loss $11.3M; NDA for DCCR in PWS on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $169.7M at Dec 31, 2023, boosted by $129M Oct 2023 offering and $43.1M warrant exercises.","R&D expenses rose to $8.7M (Q4 2023) vs $3.8M (Q4 2022); full-year $25.2M vs $15.3M.","Corrected G&A for Q4 2023: $4.1M vs previously reported $4.4M; full-year $13.5M vs $9.8M.","Positive top-line data from C602 withdrawal: primary endpoint met (p=0.0022); DCCR well-tolerated.","Leadership additions: Meredith Manning as CCO, Dairine Dempsey VP Europe, Lauren Budesheim VP HR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243305,"accession_number":"0001193125-24-019500","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Soleno Therapeutics expands inducement equity plan by 500,000 shares for new hires","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board added 500,000 shares to 2020 Inducement Plan on January 24, 2024.","Plan used to grant equity awards as material inducement for new employees and M&A hires.","Amendment adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4).","Total shares authorized under the Plan now 2,500,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243304,"accession_number":"0001193125-24-003380","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Soleno Therapeutics sets 2024 executive compensation: CEO salary $640K, bonus $500K, equity grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Bhatnagar 2024 salary $640K, 2023 bonus $500K, equity: 100K options (50% cliff 1yr) + 150K RSUs (quarterly vest).","CFO Mackaness salary $460K, bonus $240K, equity: 37K options + 56K RSUs.","VP Regulatory Hirano salary $375K, bonus $153K, equity: 16K options + 24K RSUs.","Salary increases effective Jan 1, 2024; bonuses for FY2023.","Options vest 50% on first anniversary, then monthly; RSUs vest quarterly in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277986,"accession_number":"0001193125-23-247533","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-09-29T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Soleno prices $120M combined public offering and private placement of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 3M shares at $20/share, gross ~$60M; underwriter option exercised for 450k additional shares.","Concurrent private placement of 1.825M shares and 1.175M pre-funded warrants at $20/share equivalent; total ~$60M.","Combined gross proceeds ~$120M; net to Soleno ~$64.5M from offering; expected close Oct 2, 2023.","Proceeds to advance lead candidate DCCR for Prader-Willi syndrome through late-stage development and regulatory approval.","Lead underwriters: Guggenheim, Cantor Fitzgerald, Oppenheimer; Laidlaw as lead manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277985,"accession_number":"0001193125-23-243881","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["1.02","8.01"],"status":"ready","headline":"Soleno terminates at-the-market offering agreement with Cantor Fitzgerald; $7.67M sold out of $8.88M authorized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald effective September 26, 2023.","Under the ATM prospectus, $7.67M of common stock sold out of $8.88M authorized capacity.","No further sales of common stock will be made under the ATM program.","Cantor waived the termination notice period, making termination immediate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277984,"accession_number":"0001193125-23-241845","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Soleno reports positive Phase 3 results for DCCR in Prader-Willi; primary endpoint met (p=0.0022)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: HQ-CT total score difference of 5.0 at week 16 (p=0.0022) favoring DCCR over placebo.","Secondary endpoints (CGI-S, CGI-I) showed trends toward worsening in placebo group (p=0.08 and 0.09).","DCCR well-tolerated; no serious adverse events or discontinuations in DCCR group.","Positive data triggers $15M warrant exercise (8.6M shares at $1.75) within 30 days by Nantahala, Abingworth, Vivo.","Company targets NDA submission for DCCR in PWS mid-2024; FDA previously acknowledged potential for NDA support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277983,"accession_number":"0001193125-23-213940","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Soleno Therapeutics appoints Matthew Pauls to Board, expanding to seven directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to seven; Matthew Pauls appointed as Class II director effective August 15, 2023, term expiring 2026.","Pauls brings 30+ years biopharma experience; currently CEO of Savara Inc. (NASDAQ: SVRA) and former CEO of Strongbridge Biopharma.","Granted option for 15,000 shares vesting monthly over 4 years under the Company's 2014 equity plan.","Appointment comes as Soleno advances DCCR for Prader-Willi syndrome toward planned regulatory filing and potential approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277982,"accession_number":"0001193125-23-206255","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.","Top-line data expected around end of Q3 2023; could support NDA submission to FDA.","Received $10M from SPA warrant exercise; cash and equivalents $19.4M as of June 30, 2023.","Net loss for Q2 2023 was $8.5M ($0.81 per share) vs $6.7M ($0.72 per share) in Q2 2022.","R&D expenses $5.1M in Q2 2023, up from $3.7M year-over-year due to clinical progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277981,"accession_number":"0001193125-23-184587","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Soleno Therapeutics files 8-K with corporate presentation; no specific results disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation furnished under Regulation FD; no financial metrics or guidance provided in filing.","Company is a clinical-stage biotech focused on Prader-Willi syndrome; pipeline update likely in exhibit.","No material event such as earnings, M&A, or leadership change announced in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296018,"accession_number":"0001193125-23-155448","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Soleno Therapeutics stockholders approve all six proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Ernest Mario and Birgitte Volck as Class II directors with ~64.8% and ~66.7% of votes cast, respectively.","Ratified Marcum LLP as independent auditor for fiscal 2023 (5,977,682 for, 113,718 against).","Advisory say-on-pay approved (4,019,358 for, 111,424 against); board accepted three-year frequency.","Approved amended 2014 Equity Incentive Plan (3,874,198 for, 254,424 against).","Approved issuance of shares upon exercise of warrants from May 8, 2023 private placement (4,003,720 for, 132,021 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296017,"accession_number":"0001193125-23-139402","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01","3.02"],"status":"ready","headline":"Soleno completes PWS trial enrollment, gets $10M; Q1 net loss $8.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.","Received $10M from closing of December 2022 securities purchase agreement with Nantahala, Abingworth, Vivo Capital; warrants for 22.6M shares issued.","Cash and equivalents $7.9M at March 31, 2023; plus $10M received, expected to fund through top-line data.","Net loss $8.4M ($0.88 per share) vs $5.7M ($1.07) in Q1 2022; R&D expenses $5.3M vs $4.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296016,"accession_number":"0001193125-23-134588","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.","Top-line data expected Q3 2023; FDA previously acknowledged data could support an NDA submission.","Completion triggers $10 million capital infusion from Nantahala, Abingworth, and Vivo per Dec 2022 SPA.","77 patients enrolled at 17 US and 5 UK sites; 93% of total 83 patients participated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316551,"accession_number":"0001193125-23-075734","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.","Securities purchase agreement with Nantahala Capital, Abingworth, and Vivo Capital for up to $60 million in gross proceeds.","Cash and cash equivalents of $14.6 million as of December 31, 2022.","Net loss of $5.5 million for Q4 2022, compared to $2.8 million in Q4 2021.","R&D expenses were $3.8 million for Q4 2022, compared to $3.7 million in Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316550,"accession_number":"0001193125-23-048745","cik":1484565,"company_name":"SOLENO THERAPEUTICS INC","ticker":"SLNO","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Soleno Therapeutics adds 500,000 shares to inducement equity plan for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board amended 2020 Inducement Plan to increase share reserve by 500,000 shares.","Amendment adopted without stockholder approval under Nasdaq Rule 5635(c)(4).","Plan used for equity awards as material inducement for new employees not previously employed.","Total shares authorized under plan now 2,000,000 (original 1,500,000 + 500,000).","Awards may include options, RSUs, restricted stock, SARs, performance shares/units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2762890000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-24T23:59:59+00:00|316550"}